Gilteritinib (Xospata)
Jump to navigation
Jump to search
Mechanism of action
Tyrosine kinase inhibitor of FLT3, AXL, and ALK
Diseases for which it is used
History of changes in FDA indication
- 11/28/2018: Initial FDA approval for treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test.
Patient Drug Information
Also known as
- Code name: ASP2215
- Brand name: Xospata